Seaport Therapeutics, Inc. (SPTX)
| Market Cap | 943.74M |
| Revenue (ttm) | n/a |
| Net Income | -134.69M |
| EPS | -8.50 |
| Shares Out | 53.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,841 |
| Open | 16.82 |
| Previous Close | 16.68 |
| Day's Range | 16.61 - 17.89 |
| 52-Week Range | 14.85 - 28.38 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.00 (+109.87%) |
| Est. Earnings | Nov 5, 2026 |
About SPTX
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SPTX stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 109.87% from the latest price.
News
Seaport Therapeutics initiated with a Buy at Canaccord on MDD potential
As previously reported, Canaccord analyst Sumant Kulkarni initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $28 price target Lead candidate GlyphAllo is in the Phase 2 BUOY-1…
Seaport Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $28 price target
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.
Seaport Therapeutics presents additional PK data from Phase 1 GlyphAgo trial
Seaport Therapeutics (SPTX) announced the presentation of Phase 1 clinical data for GlyphAgo at the 39th European College of Neuropsychopharmacology Congress, taking place October 10-13, 2026, in Muni...
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the ...
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
Seaport announces first patient dosed in Phase 2a trial of GlyphAgo
Seaport Therapeutics (SPTX) announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo, in adults with generalized anxiety disorder and sleep disturb...
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.
Seaport Therapeutics initiated with a Strong Buy at Raymond James
Raymond James analyst Tiago Fauth initiated coverage of Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 price target The firm sees a multi-year Glyph portfolio, with GlyphAllo’s Phase…
Seaport Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Lead programs GlyphAllo and GlyphAgo are advancing through phase II trials, targeting major depressive disorder and generalized anxiety disorder, with key data readouts expected in 2027 and 2028. The Glyph platform enables oral delivery of challenging molecules, and the company is well-funded through 2029.
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Seaport Therapeutics Slides: Conference presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines...
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
Seaport Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo target depression and anxiety with promising clinical data and registration-enabling trials planned. The platform's versatility and AI-driven efficiencies position it for broader applications.
Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint
Seaport Therapeutics (SPTX) announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, a novel, Glyphed oral prodrug of allopregnanolone, in healthy volunteers. The tri...
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference.
Seaport Therapeutics initiated with a Buy at Jones
Jones analyst Justin Walsh initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $32 price target The clinical-stage biotechnology company is developing novel treatments for depressi...
Seaport Therapeutics reports Q2 EPS ($1.78), consensus (66c)
“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our…
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
Seaport Therapeutics Earnings release: Q2 2026
Seaport Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Seaport Therapeutics Quarterly report: Q2 2026
Seaport Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.